Open AccessA Case of Organizing Pneumonia (OP) Associated with Pembrolizumab
Author(s) -
Paraskevi C. Fragkou,
Maria Souli,
Maria Theochari,
Christina Kontopoulou,
Stelios Loukides,
Anna Koumarianou
Publication year - 2016
Publication title -
drug target insights
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.297
H-Index - 12
ISSN - 1177-3928
DOI - 10.33393/dti.2016.1420
Subject(s) - pembrolizumab , medicine , metastatic melanoma , organizing pneumonia , monoclonal antibody , immunotherapy , pneumonia , cryptogenic organizing pneumonia , nivolumab , bronchoalveolar lavage , melanoma , immune system , oncology , immunology , pathology , antibody , cancer research , lung
Until recently, chemotherapy for metastatic melanoma had disappointing results. The identification of immune checkpoints such as CTLA-4 and PD-1/PD-L1 has led to the development of an array of monoclonal antibodies (Mabs). These immunologic approaches against tumoral cells come with a novel kind of side effects that the clinician needs to be familiarized with. Herein, we report for the first time a case of organizing pneumonia, based on imaging and cytological analyses of bronchoalveolar lavage, possibly associated with the use of pembrolizumab, an anti-PD-1 Mab recently approved for the treatment of metastatic melanoma.